The complaint alleges that throughout the Class Period, the Company made material misrepresentations about the U.S. Food and Drug Administration's approval process for its drug, KANGIO™. During a February 25, 2016 earnings call, Eagle Pharmaceuticals' CEO stated that the Company seemed "to be on track for a March 19 approval" of its anticoagulant drug KANGIO. However, on March 18, 2016, Eagle Pharmaceuticals announced that it had received a Complete Response Letter from the FDA stating that the FDA "cannot approve the application in its present form and requested additional information" regarding the substances used in KANGIO.
If you suffered a loss in Eagle Pharmaceuticals you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/eagle-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
Logo - http://photos.prnewswire.com/prnh/20140904/143045
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investor-alert-the-law-offices-of-vincent-wong-reminds-investors-of-a-class-action-involving-eagle-pharmaceuticals-inc-and-a-lead-plaintiff-deadline-of-august-1-2016---egrx-300295879.html
SOURCE The Law Offices of Vincent Wong